Achim Rittmeyer

TL;DR: Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations, and overall survival improvement was similar in patients with squamous non-squamous lung cancer.

TL;DR: This open-label, phase 2 randomised controlled trial assessed efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analysed by PD-L1 expression levels on tumours and tumour-infiltrating immune cells and in the intention-to-treat population.

TL;DR: IMpower130 aimed to assess the efficacy and safety of atezolizumab plus chemotherapy versus chemotherapy alone as first-line therapy for non-squamous non-small-cell lung cancer and the intention-to-treat wild-type population.

TL;DR: It is shown that high bTMB is a clinically actionable biomarker for atezolizumab in NSCLC, and a blood-based DNA sequencing assay to infer tumor mutational burden in the absence of tumor biopsy predicts response to PD-L1 blockade in patients with non-small-cell lung cancer.

TL;DR: The results of the updated ITT850 and initial ITT1225 analyses were consistent with those of the primary efficacy analysis demonstrating survival benefit with atezolizumab versus with docetaxel and continued to demonstrate a favorable safety profile after longer treatment exposure and follow-up.